Can I read Acrivon Therapeutics Financial Overview on EtoBox?

Acrivon Therapeutics Financial Overview by Malepati Mahinder Kumar Riant is a document available to read on EtoBox.

What is Acrivon Therapeutics Financial Overview about?

Acrivon Therapeutics, listed on NYSE under ACRV, is currently priced at $7.16 with a trailing P/E ratio of NMF and no dividend yield. The company focuses on developing precision oncology medicines using its proprietary platform, Acrivon Predictive Precision Proteomics (AP3), to match treatments to patients. Acrivon is advancing its lead candidate, ACR-368, which aims to predict patient responses to its therapies.

Author

Malepati Mahinder Kumar Riant

Language

EN